Home / Stocks / Health X Platform Limited
HEALTHX

Health X Platform Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹272.5

Change

-2.35 (-0.86%)

Open

₹276.0

Prev. Close

₹274.85

Day High

₹276.0

Day Low

₹272.3

Volume Analysis

Traded

1,007

Delivered

920

Delivery %

91.36%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (3)

  • •Low return on equity (0.44%)
  • •Below-average fundamentals quality score (49/100)
  • •Low operating margin (-4.0%)

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹278.6 ₹277.3 ₹274.9 ₹273.6 ₹271.2 ₹269.9 ₹267.5
Fibonacci ₹277.3 ₹275.89 ₹275.01 ₹273.6 ₹272.19 ₹271.31 ₹269.9
Camarilla ₹273.52 ₹273.18 ₹272.84 ₹273.6 ₹272.16 ₹271.82 ₹271.48

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

-1.21%

1 Month

+0.52%

3 Months

-9.42%

6 Months

-5.73%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹40.7

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

-3.02%

Net margin -1.39% × asset turnover 1.46x × equity multiplier 1.49x

Company Overview

Sector

Healthcare

Market Cap

₹862 Cr

P/E (TTM)

510.0

ROE

0.44%

Book Value

₹199.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Health X Platform Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 49/100. The strongest factor is Financial Strength (100/100), while Momentum (15/100) is the weakest area to weigh before deciding. Notably: Low return on equity (0.44%); below-average fundamentals quality score (49/100). FII holding has been rising.

TopFund Score — Fundamentals Quality

49/100 — Weak

Data confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

72

Valuation

25

Cash Flow

39

Corporate Governance

56

Momentum

15

Institutional Ownership

53

Business Quality

20

Risk & Volatility

62

Liquidity

50

From Screener.in

  • +Company is almost debt free.
  • +Company is expected to give good quarter
  • +Company's median sales growth is 36.1% of last 10 years
  • +Company's working capital requirements have reduced from 44.5 days to 28.3 days
  • −Company has low interest coverage ratio.
  • −Company has a low return on equity of 2.11% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Q2 FY27 earnings conference call audio recording shared on 16 November 2026.

Please find attached the Newspaper publication of unaudited financial results for the quarter and half year ended 30th September, 2026

Please find attached the Investor Presentation.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 358 374 307 270 274 281 286 298 301 346 374 447 484
Expenses + 355 371 317 273 278 305 311 292 324 356 399 455 506
Operating Profit 3 3 -11 -2 -5 -24 -25 6 -23 -10 -25 -8 -22
OPM % 0.9% 0.9% -3.5% -0.9% -1.7% -8.0% -9.0% 2.0% -8.0% -3.0% -7.0% -1.9% -4.6%
Other Income + 10 20 18 29 -167 -14 22 25 5 14 13 13 10
Interest 0 0 0 0 0 0 0 0 0 0 0 1 1
Depreciation 2 2 3 2 1 1 1 1 1 2 2 2 3
Profit before tax 11 21 5 25 -174 -39 -5 30 -19 1 -15 2 -15
Tax % -23.0% 4.0% -583.0% -103.0% -13.0% 2.0% -478.0% 12.0% -17.0% 60.0% -12.0% -1.0% -16.0%
Net Profit + -12 -3 22 41 -155 -38 18 27 -15 0 -13 2 -13
EPS in Rs -3 0 5 10 -34 -8 4 8 -4 0 -4 1 -3
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 41 33 -2 -20 -24 -25 -7 10 10 23 31 50 61

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 52 89 135 162 222 388 551 1,798 1,060 1,432 1,159 1,375 1,650
Expenses + 62 116 155 175 255 440 561 684 1,168 1,456 1,177 1,371 1,717
Operating Profit -10 -28 -20 -13 -33 -52 -10 1,114 -107 -24 -19 4 -66
OPM % -19.0% -31.0% -15.0% -8.0% -15.0% -13.0% -1.9% 62.0% -10.0% -1.7% -1.6% 0.3% -4.0%
Other Income + 2 0 2 7 0 1 1 3 -5 4 -179 1 50
Interest 1 2 3 1 3 1 3 3 2 1 0 1 2
Depreciation 6 7 7 6 6 5 4 4 8 9 6 7 9
Profit before tax -15 -37 -28 -12 -42 -58 -16 1,109 -122 -30 -204 -2 -27
Tax % 0.0% -1.0% 2.0% 19.0% 3.0% -9.0% 4.0% 22.0% -19.0% -119.0% -34.0% -39.0% —
Net Profit + -15 -37 -29 -15 -43 -52 -17 865 -99 6 -134 -1 -23
EPS in Rs -5 -12 -9 -4 -12 -12 -3 197 -23 3 -29 0 -6
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth 72 70 52 20 37 75 42 226 -41 35 -19 19 41

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 223 186 163 144 111 178 168 795 722 731 638 609 601
Borrowings + 5 19 21 12 2 8 12 2 9 4 1 26 49
Other Liabilities + 22 20 35 48 86 98 80 449 441 383 300 264 264
Total Liabilities 281 256 251 235 230 316 293 1,278 1,204 1,149 970 930 945
Fixed Assets + 137 126 125 117 116 114 110 93 107 110 102 117 138
CWIP 3 0 0 1 1 0 0 0 1 0 10 1 5
Investments 22 10 17 46 36 56 43 666 513 676 575 519 448
Other Assets + 119 120 110 71 77 146 139 518 583 363 283 294 355
Total Assets 281 256 251 235 230 316 293 1,278 1,204 1,149 970 930 945
Equity Capital 32 32 32 32 32 32 32 32 32 32 32 32 32

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -12 -12 -2 -49 -30 -69 -31 -207 -112 36 -17 -74
Cash from Investing Activity + 7 -1 4 15 -2 -22 21 220 133 -34 -1 171
Cash from Financing Activity + 4 13 5 33 26 103 4 -11 -2 -2 0 -80
Net Cash Flow -1 0 7 -2 -6 11 -5 1 19 0 -19 18
Free Cash Flow -28 -18 0 -55 -33 -71 -31 -212 -128 22 -27 -89
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 106 43 17 377 89 133 288 -8 104 -172 68 -1,729

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 73.92% → 74.07%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 24.73% 24.57% 24.12% 23.11% 22.5% 22.21% 21.79% 21.65% 20.99% 20.38% 21.02% 20.98%
Promoters 73.92% 73.92% 73.92% 73.92% 73.93% 74.11% 74.24% 74.24% 74.69% 74.84% 74.07% 74.07%
FII 0.49% 0.56% 0.61% 0.99% 1.71% 1.6% 1.88% 2.04% 2.25% 2.17% 2.29% 2.32%
DII 0.86% 0.96% 1.35% 1.98% 1.85% 2.06% 2.09% 2.07% 2.07% 2.6% 2.6% 2.61%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Health X Platform Limited (this stock) 862 510.0 1.36 0.44%
Kilitch Drugs India Ltd 805 33.4 2.79 10.6%
Shree Ganesh Remedies Ltd 798 65.9 4.79 10.8%
Themis Medicare Ltd. 929 624.0 2.33 0.41%
Zim Laboratories Limited 756 365.0 2.59 1.59%
Gaudium Ivf N Women H L 740 32.0 4.55 24.6%
Lincoln Pharma Ltd 1,032 10.6 1.27 12.0%

Which Mutual Funds Hold Health X Platform Limited?

Frequently Asked Questions about Health X Platform Limited

Community Sentiment

What are other investors saying about Health X Platform Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.